Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Collier
Gregory Collier, Ocean Grove AU
| Patent application number | Description | Published |
|---|---|---|
| 20090143571 | NOVEL GENES AND THEIR USE IN THE MODULATION OF OBESITY, DIABETES AND ENERGY IMBALANCE - The present invention relates generally to nucleic acid molecules encoding proteins associated with the modulation of obesity, diabetes and/or metabolic energy levels. More particularly, the present invention is directed to nucleic acid molecules and the recombinant and purified proteins encoded thereby and their use in therapeutic and diagnostic protocols for conditions such as obesity, diabetes and energy imbalance. The subject nucleic acid molecules and proteins and their derivatives, homologs, analogs, chemical equivalents and mimetics are proposed as therapeutic and diagnostic agents for obesity, diabetes and energy imbalance. | 06-04-2009 |
Gregory Royce Collier, Barwon Heads AU
| Patent application number | Description | Published |
|---|---|---|
| 20110003740 | INSULIN SENSITISERS AND METHODS OF TREATMENT - The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods. | 01-06-2011 |
| 20110112167 | THERAPEUTIC AGENTS AND TARGETS - The present invention relates to diagnostic and therapeutic methods in relation to diabetic complications, such as blindness, nephropathy and cardiovascular disease, and inflammatory conditions, such as angina, arthritis, empyema pharyngitis and urinary tract infection. Diagnostic methods involve screening for up regulated expression of decor (Den) or thioredoxin-like protein 19 (TLP 19). Therapeutic methods involve modulation of expression or activity o Den or TLP 19. The invention also relates to screening methods for identifying functional signal sequences to screen for secreted, membrane-bound and exported proteins and cell surface receptors. | 05-12-2011 |
Greg Royce Collier, Victoria AU
| Patent application number | Description | Published |
|---|---|---|
| 20110318270 | DRUG IDENTIFICATION PROTOCOL FOR TYPE 2 DIABETES BASED ON GENE EXPRESSION SIGNATURES - It relates generally to the field of drug identification and evaluation and therapeutic optimization. More particularly, it provides a protocol for identifying compounds useful in the treatment of TNFα associated diabetes or a condition associated with diabetes based on a signature of genomic or proteomic expression. Diagnostic and prognostic protocols for diabetes and conditions associated therewith are also provided. Further, optimization of therapeutic intervention is also provided. | 12-29-2011 |
Judi Collier, New South Wales AU
| Patent application number | Description | Published |
|---|---|---|
| 20090199499 | COMPOSITE BUILDING BLOCK HAVING MOISTURE BARRIER AND INSULATION ELEMENT - A construction block for use in the construction of elemental structures, including a body having a bottom surface, a top surface, end surfaces, an outer surface which forms part of an outer surface of a structure and an inner face. At least one formation on or in at least the inner face and/or at least one of the end faces receives and retains at least one insulating element. The insulating element provides thermal insulation for the structure formed from such construction blocks. | 08-13-2009 |
Paul Anthony Collier, Western Australia AU
| Patent application number | Description | Published |
|---|---|---|
| 20100028313 | COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS - The present invention concerns methods and compositions for prophylactic or therapeutic treatment of skin disorders by administering therapeutically or prophylactically effective amounts of a probiotic. The present invention is also concerned with the treatment of symptoms of skin disorders. | 02-04-2010 |
Peter Collier, New South Wales AU
| Patent application number | Description | Published |
|---|---|---|
| 20090199499 | COMPOSITE BUILDING BLOCK HAVING MOISTURE BARRIER AND INSULATION ELEMENT - A construction block for use in the construction of elemental structures, including a body having a bottom surface, a top surface, end surfaces, an outer surface which forms part of an outer surface of a structure and an inner face. At least one formation on or in at least the inner face and/or at least one of the end faces receives and retains at least one insulating element. The insulating element provides thermal insulation for the structure formed from such construction blocks. | 08-13-2009 |
Peter Collier, Bilpin AU
| Patent application number | Description | Published |
|---|---|---|
| 20100047492 | BUILDING BLOCKS - A cementitious mix for preparing a building block wherein the mix includes the ingredients; sand, cement, sawdust and water; wherein said sawdust comprises the greater proportion of the mix constituents; and wherein the dry density of the mix ranges between 700 kg/m | 02-25-2010 |
Steven J. Collier, Tanglin Park SG
| Patent application number | Description | Published |
|---|---|---|
| 20100069651 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL - The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: | 03-18-2010 |
| 20110263878 | PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL - The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: | 10-27-2011 |
Steven James Collier, Singapore SG
| Patent application number | Description | Published |
|---|---|---|
| 20100151534 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE - The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N,N-dimethyl-3-keto-3-(2-thienyl)-1-ketopropanamine to (S)—N,N-dimethyl-3-hydroxy-3-(2-thienyl)-1-propanamine. | 06-17-2010 |
| 20100173369 | KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE - The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds. The engineered ketoreductase polypeptides are optimized for catalyzing the conversion of N-methyl-3-keto-3-(2-thienyl)-1-propanamine to (S)—N-methyl-3-hydroxy-3-(2-thienyl)-1-propanamine. | 07-08-2010 |
Steven James Collier, The Galen SG
| Patent application number | Description | Published |
|---|---|---|
| 20110111468 | VARIANT LOVD POLYPEPTIDES AND THEIR USES - The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound | 05-12-2011 |
Steven James Collier, 02-04 Tanglin Park SG
| Patent application number | Description | Published |
|---|---|---|
| 20110053941 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 03-03-2011 |
William Randolph Collier, Esterel CA
| Patent application number | Description | Published |
|---|---|---|
| 20110102974 | Modular multilevel raised floor electro-mechanical distribution system - The subject invention is directed to an improved modular multilevel raised floor electro-mechanical distribution system for installation in building structures including, but not limited to, data centers and similar rooms having high heat loads requiring usually dedicated cooling systems and usually having extensive data cabling and wiring. In addition to a walking and equipment support surface, the invention provides dedicated levels, isolated from one another and positioned under the walking surface, for distribution of electrical services, including data, on the one hand, and conditioned air, on the other. | 05-05-2011 |